| meta-analysis | Q815382 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | R Vander Stichele | |
| L Van Bortel | |||
| T De Backer | |||
| P Lehert | |||
| P2860 | cites work | Lipid-lowering for peripheral arterial disease of the lower limb | Q24243312 |
| Cilostazol for peripheral arterial disease | Q24246227 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 | ||
| Medical treatment of peripheral arterial disease | Q28194759 | ||
| Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial | Q28219117 | ||
| Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials | Q28379237 | ||
| Meta-analysis of continuous outcome data from individual patients. | Q30657054 | ||
| Oral vasoactive medication in intermittent claudication: utile or futile? | Q30908761 | ||
| Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. | Q31016826 | ||
| Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis | Q33535917 | ||
| Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). | Q33832961 | ||
| A primary care approach to the patient with claudication | Q33856081 | ||
| Exercise for intermittent claudication. | Q33908906 | ||
| Medical treatment of peripheral artery occlusive disease (PAOD). | Q34121372 | ||
| Exercise training and smoking cessation as the cornerstones of managing claudication | Q34289696 | ||
| Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985. | Q34418366 | ||
| Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). | Q34586454 | ||
| Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population | Q34930923 | ||
| Walk training and drug treatment in patients with peripheral arterial occlusive disease stage II. A review | Q35577999 | ||
| Drug treatment of intermittent claudication | Q35838378 | ||
| Pharmacological approaches to the treatment of intermittent claudication | Q36167879 | ||
| Naftidrofuryl: a review of its use in the treatment of intermittent claudication | Q36329279 | ||
| What is heterogeneity and is it important? | Q36705916 | ||
| Naftidrofuryl-induced acute hepatic necrosis | Q36707051 | ||
| How to treat hypertension in patients with peripheral artery disease | Q36829011 | ||
| Can drugs help patients with lower limb ischaemia? | Q39563497 | ||
| Drug therapy: vasodilator drugs in peripheral vascular disease | Q39786666 | ||
| Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. | Q40482544 | ||
| Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study | Q40519461 | ||
| Improved functional outcomes following exercise rehabilitation in patients with intermittent claudication | Q40743327 | ||
| Pharmacological management of intermittent claudication: a meta-analysis of randomised trials | Q40761096 | ||
| Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease | Q41214601 | ||
| Atherosclerotic peripheral arterial disease in blacks--an established problem | Q43436735 | ||
| Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program | Q43952613 | ||
| Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. | Q44450748 | ||
| Naftidrofuryl-induced liver injury | Q44485417 | ||
| Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease | Q44571608 | ||
| The relation between peripheral arterial occlusive disease and cardiovascular diseases in elderly population: a cross-section study in Wanshoulu area, Beijing | Q44671301 | ||
| Renal intratubular crystallisation of calcium oxalate and naftidrofuryl oxalate | Q44783596 | ||
| Aorto-iliac occlusive disease in the various population groups of South Africa | Q46799025 | ||
| Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases | Q49037111 | ||
| Exercise rehabilitation improves functional outcomes and peripheral circulation in patients with intermittent claudication: a randomized controlled trial | Q49214643 | ||
| Noninvasively diagnosed peripheral arterial disease as a predictor of mortality: results from a prospective study | Q49293464 | ||
| Epidemiology and prognosis of peripheral obliterative arteriopathy | Q50853928 | ||
| Quality of life and objective disease criteria in patients with intermittent claudication in general practice | Q51032715 | ||
| A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication | Q52886997 | ||
| A multilevel model framework for meta-analysis of clinical trials with binary outcomes | Q52927136 | ||
| The effect of naftidrofuryl on intermittent claudication: a meta-analysis | Q67894281 | ||
| Acute cytolytic hepatitis probably caused by naftidrofuryl | Q68842121 | ||
| [Massive poisoning by naftidrofuryl with severe disorders of rhythm and conduction] | Q69240909 | ||
| Calcium oxalate crystalluria in elderly patients and treatment with naftidrofuryl oxalate | Q70969628 | ||
| Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study | Q72571573 | ||
| Effects of exercise training program on functional capacity and quality of life in patients with peripheral arterial occlusive disease. Evaluation of a pilot project | Q77934497 | ||
| A non-randomised controlled trial of the clinical and cost effectiveness of a Supervised Exercise Programme for claudication | Q79400432 | ||
| [Vasoactive agents and prostanoids in the therapy of PAD: facts, questions, disproven assumptions] | Q80102671 | ||
| A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences | Q80418532 | ||
| The ankle-brachial pressure index and a standardized questionnaire are easy and useful tools to detect peripheral arterial disease in non-claudicating patients at high risk | Q80592478 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heterocyclic compound | Q193430 |
| intermittent claudication | Q1097957 | ||
| claudication | Q2888709 | ||
| vasodilator agent | Q4008956 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | b603 | |
| P577 | publication date | 2009-03-10 | |
| P1433 | published in | The BMJ | Q546003 |
| P1476 | title | Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data | |
| P478 | volume | 338 |
| Q38657444 | Current therapies and investigational drugs for peripheral arterial disease |
| Q37984281 | Preventive aspects in peripheral artery disease |
| Q37983543 | Supervised exercise therapy for intermittent claudication: current status and future perspectives. |
| Q31102027 | Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. |
Search more.